Table 3 Heart rate and heart dimensions
|  | Liraglutide (n = 23) | Placebo (n = 26) | Mean (95% CI) changes from baseline (liraglutide vs placebo) | p value | ||||
|---|---|---|---|---|---|---|---|---|
Baseline | 26Â week | Mean (SD) change from baseline | Baseline | 26Â week | Mean (SD) change from baseline | |||
Heart rate in bpm (SD) | 72 (9) | 75 (10) | 4 (8) | 77 (13) | 76 (13) | − 1 (6) | 4.3 (0.2 to 8) | 0.04 |
LV filling volume in mL (SD) | 82 (17) | 76 (17) | − 5 (15) | 74 (17) | 82 (21) | 7 (10) | − 11 (− 18 to − 3) | 0.01 |
LA volume index in mL/m2 (SD) | 36 (8) | 35 (7) | − 1 (6) | 32 (8) | 34 (10) | 1 (7) | − 2 (− 6 to 2) | 0.38 |
LVEDV in mL (SD) | 147 (25) | 141 (25) | − 5 (14) | 138 (33) | 144 (38) | 6 (16) | − 11 (− 20 to − 2) | 0.02 |
LVESV in mL (SD) | 67 (14) | 66 (14) | − 0 (9) | 62 (17) | 63 (20) | 1 (9) | − 1 (− 7 to 4) | 0.69 |
LVM in g (SD) | 107 (18) | 105 (18) | − 2 (8) | 108 (27) | 110 (29) | 4 (9) | − 6 (− 11 to − 1) | 0.03 |
LVMI in g/m2 (SD) | 49 (6) | 49 (6) | − 0 (3) | 50 (11) | 52 (12) | 2 (4) | − 1.5 (−3.6 to 0.6) | 0.17 |
LVMI/LVEDVI g/mL/m2 (SD) | 0.73 (0.10) | 0.75 (0.11) | 0.01 (0.07) | 0.79 (0.14) | 0.77 (0.14) | − 0.00 (0.08) | 0.01 (− 0.03 to 0.06) | 0.60 |
LV compliance (SD) | 23.4 (10.4) | 24.1 (8.3) | 0.7 (9.7) | 19.5 (8.0) | 18.6 (8.2) | − 0.3 (6.8) | 3 (− 1 to 7) | 0.14 |